Labiotech.eu

News and Trends 23 May 2018

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 23 May 2018

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 22 May 2018

Celgene Partners With German Biotech to Develop Oncology Treatments

Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […]

May 22, 2018 - 2 minutesmins - By Alexander Burik

Poland emerging biotech pharmaceutical companies

In Depth 22 May 2018

Poland’s Emerging Biotech Sector: The Time Is Right for Startups

Poland might not be the first place you associate with biotech, but the country is becoming an emerging hotspot for pharmaceutical companies and biotech startups. Although Poland has a very strong scientific base in life sciences and medicine, it has not developed a vibrant biotech or medtech sectors. Until recently, no truly innovative products from […]

May 22, 2018 - 6 minutesmins - By External Contributor

Interview 21 May 2018

Engineering Red Blood Cells to Fight the Most Severe Cancers

Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is now near the finish line to launch the first red blood cell therapy. How amazing would it be if we could use our own cells […]

May 21, 2018 - 6 minutesmins - By Alexander Burik

More News! 18 May 2018

New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech

Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other similar conditions. The therapy (BN201) is the first its class and if successful in clinical trials will be the only treatment that can help repair […]

May 18, 2018 - 2 minutesmins - By Helen Albert

Startup Scout 18 May 2018

This French Biotech Targets Retinal Cells to Treat Blindness

Today, we’re in Paris, visiting SparingVision, a biotech trying to combat blindness using a protein that slows down the degeneration of cone cells in the retina. Mission: SparingVision uses a naturally occurring protein called rod-derived cone-viability factor, which binds to a transmembrane peptide on cone photoreceptor cells in the retina and allows more glucose to enter […]

May 18, 2018 - 2 minutesmins - By Alexander Burik

More News! 17 May 2018

The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma

iSTAR Medical has obtained promising results from the first-in-human trial of an eye implant, that can decrease fluid pressure in the eyes of glaucoma patients. iSTAR Medical, a Belgian biotech, has six-month results from a first-in-human trial showing the effects of its device on intraocular pressure in patients with glaucoma — a condition where high eye […]

May 17, 2018 - 2 minutesmins - By Alexander Burik

More News! 17 May 2018

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […]

May 17, 2018 - 2 minutesmins - By Helen Albert

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […]

May 16, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Celgene Partners With German Biotech to Develop Oncology Treatments

Poland’s Emerging Biotech Sector: The Time Is Right for Startups

Engineering Red Blood Cells to Fight the Most Severe Cancers

New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech

This French Biotech Targets Retinal Cells to Treat Blindness

The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!